India's first nasal vaccine, developed by Bharat Biotech in collaboration with the Department of Biotechnology and its PSU, the Biotechnology Industry Research Assistance Council (BIRAC), got regulatory approval for Phase 2/3 trials on Friday. 

Giving an update for the same, a statement by the Ministry of Science & Technology statement said, "Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials. This is the first of its kind COVID-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. BBIL has in-licensed technology from Washington University in St Louis, USA." 

The company reported that the phase 1 clinical trials have been completed for the ages of 18 to 60 years. The doses administered to healthy volunteers in the Phase I trial have been well-tolerated and no serious adverse events were reported, the company said.